1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

15 Sep 2023
Admin
News Article

Pharmazz and Sun Pharmaceutical Industries Enter into Agreement

Pharmazz has entered into a licence agreement with Sun Pharmaceutical Industries to introduce Tyvalzi™ (Sovateltide) in India.

Under the terms of the agreement, Sun Pharma has been granted the rights to market Sovateltide in India, utilising the brand name Tyvalzi™ (Sovateltide). In return, Pharmazz will receive upfront and milestone payments, including royalties.

Tyvalzi™ is a new drug designed to address acute cerebral ischaemic stroke, a condition characterised by the interruption of blood supply to the brain, leading to potential brain damage, neurological deficits, or even death.

The mechanism of action of Tyvalzi™ involves the promotion of neurovascular remodelling, including the formation of new neurons (neurogenesis) and blood vessels (angiogenesis). Additionally, it offers protection to neural mitochondria and enhances their biogenesis.

Sovateltide (Tyvalzi™) has been approved as a new, effective, and well-tolerated therapy for treating patients with cerebral ischaemic stroke. It has shown statistically significant and clinically meaningful improvements in neurological outcomes.

Currently, there have been no new drugs approved for the treatment of stroke in over two decades, aside from rTPA. Sovateltide (Tyvalzi™), as a selective endothelin B receptor agonist, represents a groundbreaking development and can be administered up to 24 hours following a cerebral ischaemic stroke.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!